Earnings ·
Genmab reports $4,239 million in third-quarter DARZALEX net sales
GMABGenmab A/S
Genmab announced that worldwide net trade sales of DARZALEX (daratumumab) for the third quarter of 2026 totaled USD 4,239 million. This figure includes both intravenous and subcutaneous formulations reported by licensee Johnson & Johnson. Sales in the U.S. accounted for USD 2,528 million, while the rest of the world contributed USD 1,711 million. Genmab receives royalties on these worldwide net sales under an exclusive license agreement with J&J to develop, manufacture, and commercialize daratumumab. This disclosure provides key revenue metrics from its primary commercial partner for the quarter.